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4Department of Pathology, Hospital de Cĺınicas de Porto Alegre, Ramiro Barcelos 2350, 90.035-903 Porto Alegre, RS, Brazil
5Department of Internal Medicine, Faculty of Medicine, Federal University of Rio Grande do Sul, Hospital de Cĺınicas de Porto Alegre,
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RC-3095, a selective GRPR antagonist, has been shown to have anti-inflammatory properties in different models of inflammation.
However, its protective effect on lungs submitted to lung ischemia-reperfusion injury has not been addressed before. Then, we
administrated RC-3095 intravenously before and after lung reperfusion using an animal model of lung ischemia-reperfusion
injury (LIRI) by clamping the pulmonary hilum. Twenty Wistar rats were subjected to an experimental model in four groups:
SHAM, ischemia-reperfusion (IR), RC-Pre, and RC-Post.The final mean arterial pressure significantly decreased in IR and RC-Pre
compared to their values before reperfusion (𝑃 < 0.001). The RC-Post group showed significant decrease of partial pressure of
arterial oxygen at the end of the observation when compared to baseline (𝑃 = 0.005). Caspase-9 activity was significantly higher
in the RC-Post as compared to the other groups (𝑃 < 0.013). No significant differences were observed in eNOS activity among
the groups. The groups RC-Pre and RC-Post did not show any significant decrease in IL-1𝛽 (𝑃 = 0.159) and TNF-𝛼 (𝑃 = 0.260),
as compared to IR. The histological score showed no significant differences among the groups. In conclusion, RC-3095 does not
demonstrate a protective effect in our LIRImodel. Additionally, its use after reperfusion seems to potentiate cell damage, stimulating
apoptosis.
1. Introduction
Lung ischemia reperfusion injury (LIRI) is the main cause of
early graft dysfunction and death after lung transplantation
[1]. Pulmonary edema constitutes its most frequent clinical
manifestation, which is triggered by an excessive release of
proinflammatory mediators, reactive oxygen species (ROS),
cytokines, and neutrophil infiltration in the lungs [2–4].
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Ischemia causes an imbalance between metabolic supply and
demand, leading to tissue hypoxia, cellular damage, anddeath
[5].
Several methods and substances have been used as an
attempt to protect the lungs during the early phase of
posttransplantation and to improve short- and long-term
graft performance; however, these efforts have generated
limited results [6, 7]. The techniques include lung protective
ventilation [8, 9], appropriate fluid management, the opti-
mization of organ preservation in lung transplantation, and
the minimization of ventilation and anoxic ischemic time
[10].
The gastrin-releasing peptide (GRP) is a neuropeptide
that acts through G protein-coupled receptors [11]. It partici-
pates in signal transmission in both the central and peripheral
nervous systems [11, 12]. Its preferred receptor, gastrin-
releasing peptide receptor (GRPR), is expressed by various
cell types, including those of the gastric, respiratory, and
nervous systems, and it is overexpressed in tumor cells [12].
Recent studies have demonstrated the relationship between
GRPR signaling and inflammation [13]. GRPR is involved in
the induction of innate and adaptive immune responses by
inducing mast cell chemotaxis, macrophage migration, and
T cell and fibroblast proliferation [14].
RC-3095, a selective GRPR antagonist, has been shown
to have anti-inflammatory properties in murine models of
arthritis, gastritis, uveitis, and sepsis by attenuating the
release of proinflammatory cytokines such as tumor necrosis
factor-alpha (TNF-𝛼) and interleukin-1-beta (IL-1𝛽) and the
activation and migration of mononuclear cells to sites of
inflammation [15]. In addition, GRP mediates air pollution-
induced airway hyperreactivity and inflammation in rodents
[13].
Because GRPR signaling has been shown to be a relevant
component of the inflammatory response in various experi-
mental models and the excessive release of proinflammatory
mediators and cytokines, as well as neutrophil infiltration in
the lung, is a central event for the development of LIRI, we
hypothesized that the GRPR antagonist, RC-3095, imparts a
protective effect on LIRI.
2. Materials and Methods
The animals were handled in accordance with the Animal
Welfare Act and the Guidelines for the Care and Use of
Laboratory Animals (NIH Publication, revised 1996). The
Ethical Committee of the Hospital de Cĺınicas de Porto
Alegre approved the experimental protocols.
2.1. Experimental Protocol. Twenty Wistar male rats with a
mean weight of 360 g were randomly assigned to one of four
treatment groups (𝑛 = 5): simulation of surgery (SHAM),
ischemia-reperfusion (IR), RC-Pre (RC-3095 Pre-LIRI), and
RC-Post (RC Post-LIRI). RC-3095 was administered as a
single dose to the left jugular vein 15min before the induction
of ischemia (RC Pre-IR group) and immediately after clamp
removal (RC Post-IR group). All animals were observed for
120min after reperfusion. RC-3095 (0.3mg/1mL)was diluted
in normal saline, following the protocol described in previous
studies conducted by our research group [13].
The animals were subjected to induction anesthesia with
0.5 L/min of oxygen flow and isoflurane (100mL/min). Rats
were systemically heparinized (1mg/kg) parenterally and
underwent cervical tracheostomy with a plastic cannula
(Abbocath #14, Abbott Laboratories, Abbott Park, IL, USA).
Anesthesia was then maintained using 0.2 L/min of
oxygen flow and isoflurane (10mL/min). The animals were
mechanically ventilated with room air (Harvard Rodent Ven-
tilator, Model 683, Harvard Apparatus Co., Millis, MA, USA)
using a tidal volume of 8mL/kg body weight, a respiratory
rate of 70–80 breaths/min, and a positive end-expiratory
pressure of 2 cm H
2
O.
Themean arterial pressure (MAP)wasmeasured through
cannulation of the right carotid artery (Sirecust 730, Siemens,
Solna, Sweden), which was also used for collecting samples
for arterial blood gas analysis (Blood Gas Analyzer, Siemens
Bayer 865, Siemens).
Left thoracotomy was performed in the fifth intercostal
space, the pulmonary ligament was sectioned, and sub-
sequently, the left pulmonary hilum was clamped (Vicca
Neuroclip, Cachoeirinha, RS, Brasil). Immediately before
clamping, lung expansion was achieved through occlusion of
the expiratory valve for three inspiratory cycles to prevent
alveolar collapse and consolidation. During the clamping
period, both lungs were maintained on mechanical ventila-
tion using the settings previously described [16].
MAP and arterial blood gases were measured before
thoracotomy (baseline), after ischemia (predetermined 45-
min), and at the end of the experiment. After the 120 min
reperfusion period, the animals were sacrificed by incision
of the abdominal aorta. Hemodynamic, gas exchange, and
pulmonary mechanics were measured at baseline, after lung
injury, and after 120min of observation.
2.2. Measurement of Cytokine Levels. Tissues of the right
and left lungs were sectioned, weighed, and stored at −80∘C.
Homogenates were prepared by incubating the tissues in a
tissue lysis buffer containing 10% Triton X-100 dissolved in
a solution consisting of 100mM Tris (pH 7.5), 10mM EDTA,
100mM sodium fluoride, 100mM sodium pyrophosphate,
10mM sodium orthovanadate, 10 𝜇g/mL aprotinin, 1𝜇g/mL
leupeptin, and 2mM PMSF, for 30min on ice. Immediately
after incubation, the samples were centrifuged at 13,000 rpm,
4∘C for 20min. The supernatants were submitted for protein
quantification by the Bradford method [17], using a standard
curve from 50 to 1,000 𝜇g/mL of bovine serum albumin and
the Bradford reagent (0.01% coomassie brilliant blue, 47%
ethanol, 8.5% phosphoric acid, and distilled water q.s.p); the
absorbance was determined at a wavelength of 595 nm.
Protein quantification and expression analysis of IL-
1𝛽 and TNF-𝛼 were performed using an enzyme-linked
immunosorbent assay (ELISA) method that was specific for
each cytokine. The ELISA protocol was performed with the
Duo-set (BD Bioscience Inc., MA, USA).
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2.3. Immunohistochemical Studies. Caspase-9 and eNOS
activity were performed on serial sections prepared from
paraffin-embedded, formalin-fixed rat lungs. After paraffin
removal using xylene, the sections were rehydrated and sub-
jected to a 40 min to heat treatment at 80∘C. The specimens
were incubated in a peroxidase block reagent (BIOGEN) to
quench endogenous peroxidase activity and any nonspecific
reaction was blocked for 10min.
The sections were then incubated with primary antibod-
ies specific for caspase-9 and eNOS (Asp353, Cell Signaling)
and (H-159-Santa Cruz), respectively, at a dilution of 1 : 100,
for 2 h at room temperature, followed by incubation with
the labeled polymer for 30min. Staining was performed
by incubating the sections with diaminobenzidine tetrahy-
drochloride substrate chromogen (DAB-BIOGEN), which
resulted in a brown-colored precipitate at the antigen site.
The sections were then counterstained with hematoxylin for
visualization.
Immunohistochemical staining was scored according to
the distribution of expression of the target proteins in the
evaluated areas, namely, the nucleus, membrane, or cyto-
plasm. In addition, the intensity of immunostaining was
described as follows: 1 = mild, 2 = moderate, and 3 = strong.
A semiquantitative approach was used to measure the areas
and the intensity of staining of the tissues. A pathologist who
was blinded to the clinical and histopathologic information
independently analyzed the slides. Caspase-9 and eNOS
activity were assed using a cellSens Digital Imaging Software
(DP77 microscopy camera, BX41 Microscopy, Olympus).
2.4. Histologic Analysis
Sample Preparation. The sections of the right and left lungs
were excised and then immersed directly in 10% formalin
for 60 h; no inflation fixation method was performed. After
fixation, the lungs were separated at the hilum, and each lung
was sectioned horizontally (right and left lung). The tissue
blocks were cut from each region and embedded in paraffin
wax, fromwhich 5mm sectionswere prepared,mounted, and
stained with hematoxylin-eosin.
Two pathologists who were blinded to the experimental
protocol, the test groups, and the region of sampling per-
formed the quantitative examination by light microscopy.
Each sample was examined under both low and high power
fields, and 20 fields from each section were analyzed by one
of the pathologists. The other pathologist randomly selected
and analyzed those 20 fields from each sample.
The severity of histologic lesions was assed using a score
(HIS) that was based on six parameters: intra-alveolar edema,
hyaline membrane formation, hemorrhage, recruitment of
granulocytes into the air space, focal alveolar collapse or con-
solidation, and epithelial desquamation/necrosis of airways
or alveoli. Each parameter was evaluated semiquantitatively
using the following scale: 0 = absent, 1 = mild, 2 = moderate,
and 3=prominent. In addition, the percentage of the involved
area of each histologic specimen was estimated (0 to 100%) to
quantify any observed histologic changes [18].
For each sample, a weighted histologic score (WIS) was
computed from the product of HIS and the percentage of
area involved. The HIS andWIS scores of the dependent and
nondependent lung regions of each animal were calculated.
2.5. Statistical Analysis. The results presented in the text,
tables, and figures were expressed as the median ± interquar-
tile range.The data were analyzed using the SPSS version 16.0
statistical software (SPSS Inc., Chicago, IL, USA). Nonpara-
metric Kruskal-Wallis test was performed, followed by chi-
squared test for intergroup comparisons. A 𝑃 value of <0.05
was considered significant
3. Results
The final mean arterial pressure significantly decreased in
the IR and RC Pre-IR groups compared to the baseline (P <
0.001). The RC Post-IR group showed a significant decrease
in the partial pressure of arterial oxygen at the end of the
observation period compared to the baseline (P = 0.005)
(Table 1).
No differences in the levels of IL-1𝛽 (P=0.159) andTNF-𝛼
(P = 0.260) were observed in the RC-Pre andRC-Post groups,
compared to the IR group (Figure 1).
No significant differences in histological scores were
observed among the study groups. The RC-Post group
showed a slight reduction in the histological scores compared
to that of the other groups (Figure 2).
The caspase-9 activity of pneumocytes was significantly
higher in the RC Pos-IR group, compared to the other groups
(P < 0.013) (Figures 3 and 4). No significant differences in
eNOS activity were observed among the groups.
4. Discussion
Several studies using both animals and humans have investi-
gated the effects of pharmacologic interventions in reducing
the release of proinflammatory cytokines and chemokines,
as well as other events that are potentially related to the
development LIRI; however, these efforts have generated
unclear results [6, 16, 19, 20]
A rodent model for LIRI was selected for the present
study because this has been extensively used in the previous
reports [16, 21]. This animal model mimics several features
of LIRI such as the inflammatory changes and structural
damage to the lungs [20, 21]. Furthermore, the differences in
mean arterial pressure prior to and after reperfusion among
the groups were similar compared to those described in the
literature [20].
Only the RC Post-IR group showed a significant decrease
in the mean measurements of partial pressure of arterial
oxygen at the end of the observation, as compared to the
baseline. These results indicate that RC, when administered
after reperfusion, potentiates the harmful effects of the IR
process.
Although, the present study did not show a clear pro-
tective effect of RC on the lung ischemia reperfusion injury
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Figure 1: IL-1𝛽 and TNF-𝛼 protein expression. There was no significant differences in lung tissue protein expression among the groups in
IL-1𝛽 (P = 0.159) and TNF-𝛼 (P = 0.260). Data are presented as median ± standard error of the median.







Figure 2: Photomicrograph of the lung in the different experimental
groups. The histological score (HIS) showed no significant differ-
ence between groups (P = 0.973) (A: SHAM, B: IR, C: RC-Pre, and
D: RC-Post, magnification ×100).
model, we observed a trend in reduction of IL-1𝛽 in the RC-
Pre group, compared to that in the IR group.This effect of RC
reduction of inflammatory mediators has been demonstrated
in various conditions such as arthritis, colitis, and sepsis
[22–24]. Unfortunately, information on the level of GRPR
expression in the tissues and the GRP levels in plasma was
not available for inclusion in the analysis of the present study.
This information might have assisted in the interpretation
of our results. It is also possible that the basic mechanisms
involved in the pathogenesis of LIRI differ from those of
other inflammatory conditions whose GPRR signaling could
bemore relevant [22–24]. Additionally, there are also species-
specific pharmacological effects that could sometimes lead
to discrepancies between laboratory observations and the
findings obtained from patients with LIRI in the clinical
setting [1–4, 10].
RC-3095 was administered to animals as a single dose
before the induction of ischemia and immediately after clamp
removal.This treatment schedule and doses were comparable
to those applied by our group in previous studies performed
in rodent models [22, 23]. Thus, we could argue that the
experimental conditions were adequate for the evaluation of
the protective effects of the GRPR antagonist, particularly in
terms of dose intensity.
Although GRPR inhibition did not impart a protective
effect on our LIRI model, caspase-9 activity in pneumocytes
was significantly higher in the animals that received RC-
3095 Pos-IR, compared to the other groups. Active caspase-
9 cleaves and activates caspase-3, thereby inducing events
that lead to DNA fragmentation and cell death. This occurs
as early as 15min after treatment. Thus, once caspase-9 is
activated, a protease cascade is initiated, which in turn leads
to the rapid activation of caspase-3 and apoptosis [25]. Based
on these findings, we hypothesize that, in the presence of
RC-3095, caspase-9 was upregulated in the RC-Post group,
which activated caspase-3 and resulted in apoptosis as a
response mechanism to tissue injury. Interestingly, the RC-
Pre group did not show these alterations, suggesting that its
administration prior to reperfusion might have a beneficial
effect or at least did not induce an increase in caspase-9
activity. Additionally, in a previous study conducted by our
group, we observed an increase in the activity of caspase-3
after 45min of ischemia, which was associated with a higher
number of apoptotic cells [21].
eNOS activity mainly observed in the cytoplasm of the
endothelial layer of the lung tissue, with a similar distribution
among all groups. This finding therefore demonstrates that
this enzyme does not have any function in LIRI [26].
In conclusion, the administration of RC3095, which is a
selective GRP receptor antagonist, after reperfusion is harm-
ful to IR lungs, as indicated by the induction of apoptosis and
the decrease in PaO
2
; however, no signs of lung damage were
evident during lung histological analysis. Further studies are
6 BioMed Research International
(a) (b)
(c) (d)
Figure 3: Immunohistochemical staining for Cleaved Capase 9. There was maximum expression of brown-positive cells in pneumocytes

























Figure 4: Cleaved caspase-9 pneumocyte expression in lung tissues.
The RC-Post group exhibited a significant overexpression of cleaved
caspase-9 (P < 0.013) compared to the other groups. Data are
presented as the median ± standard error of the median.
necessary to establish the mechanism of GRPR antagonist
modulation in the setting of LIRI.
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